Phase 1 Recurrent Multiple Myeloma Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Roswell Park Cancer Institute15 enrolled1 locationNCT06622005
Recruiting
Phase 1
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
National Cancer Institute (NCI)26 enrolled14 locationsNCT06465316
Recruiting
Phase 1Phase 2
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Fred Hutchinson Cancer Center30 enrolled1 locationNCT07181941
Recruiting
Phase 1Phase 2
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Alliance for Clinical Trials in Oncology88 enrolled40 locationsNCT06232044
Recruiting
Phase 1
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
Multiple MyelomaRefractory Multiple MyelomaRecurrent Multiple Myeloma
Thomas Martin, MD30 enrolled1 locationNCT07340853
Recruiting
Phase 1
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Refractory Multiple MyelomaRecurrent Multiple Myeloma
Abdullah Khan27 enrolled1 locationNCT05981209
Recruiting
Phase 1Phase 2
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Recurrent Multiple Myeloma
Mayo Clinic37 enrolled1 locationNCT06785415